BACKGROUND: On account of the lack of predictive biomarkers of toxicity, we investigated whether polymorphisms of genes involved in fluoropyrimidine metabolism and 5-fluorouracil (5-FU) degradation rate were associated with outcomes of adjuvant capecitabine in patients with early stage gastrointestinal cancers. METHODS: Genotyping of DPYD GIVS14A, MTHFR C677T and A1298C SNPs were performed by pyro-sequencing technology. PCR analysis was used for genotyping TYMS-TSER. We also evaluated the 5-FU degradation rate, which determines the amount of drug consumed by PBMC in a time unit. Association of these variables with clinical outcome was evaluated using multivariate logistic regression analysis. RESULTS: One hundred forty-two patients with early stage colon (39%), rectal (28%), stomach (20%) and pancreatic (13%) cancer, treated with adjuvant capecitabine, were included in this retrospective analysis. Seventy and 20% of the patients suffered from at least one G1-4 and G3-4 adverse events, respectively. According to the 5-FU degradation rate, three and 13 patients were assigned as poor (<0.86 ng/mL/106 cells/min) and ultra-rapid (>2.1 ng/mL/106 cells/min) metabolizers, respectively. At a multivariate logistic regression analysis, an altered 5-FU degradation rate (values <0.86 or >2.10 ng/mL/106 cells/min) was associated with grade 3-4 adverse events (OR = 2.09, 95% CI: 1.14-3.82, P = 0.01). No correlation was reported between toxicity and gene polymorphisms except for hand-foot syndrome that was more frequent in the MTHFR 1298CC homozygous variant genotype (OR = 2.03, 95% CI 1.04-3.96, P = 0.03). CONCLUSIONS: 5-FU degradation rate may be regarded as possible predictive biomarker of capecitabine toxicity in early stage gastrointestinal cancer.
BACKGROUND: On account of the lack of predictive biomarkers of toxicity, we investigated whether polymorphisms of genes involved in fluoropyrimidine metabolism and 5-fluorouracil (5-FU) degradation rate were associated with outcomes of adjuvant capecitabine in patients with early stage gastrointestinal cancers. METHODS: Genotyping of DPYD GIVS14A, MTHFRC677T and A1298C SNPs were performed by pyro-sequencing technology. PCR analysis was used for genotyping TYMS-TSER. We also evaluated the 5-FU degradation rate, which determines the amount of drug consumed by PBMC in a time unit. Association of these variables with clinical outcome was evaluated using multivariate logistic regression analysis. RESULTS: One hundred forty-two patients with early stage colon (39%), rectal (28%), stomach (20%) and pancreatic (13%) cancer, treated with adjuvant capecitabine, were included in this retrospective analysis. Seventy and 20% of the patients suffered from at least one G1-4 and G3-4 adverse events, respectively. According to the 5-FU degradation rate, three and 13 patients were assigned as poor (<0.86 ng/mL/106 cells/min) and ultra-rapid (>2.1 ng/mL/106 cells/min) metabolizers, respectively. At a multivariate logistic regression analysis, an altered 5-FU degradation rate (values <0.86 or >2.10 ng/mL/106 cells/min) was associated with grade 3-4 adverse events (OR = 2.09, 95% CI: 1.14-3.82, P = 0.01). No correlation was reported between toxicity and gene polymorphisms except for hand-foot syndrome that was more frequent in the MTHFR 1298CC homozygous variant genotype (OR = 2.03, 95% CI 1.04-3.96, P = 0.03). CONCLUSIONS:5-FU degradation rate may be regarded as possible predictive biomarker of capecitabinetoxicity in early stage gastrointestinal cancer.
Authors: Maarten J Deenen; Jolien Tol; Artur M Burylo; Valerie D Doodeman; Anthonius de Boer; Andrew Vincent; Henk-Jan Guchelaar; Paul H M Smits; Jos H Beijnen; Cornelis J A Punt; Jan H M Schellens; Annemieke Cats Journal: Clin Cancer Res Date: 2011-04-15 Impact factor: 12.531
Authors: M Joerger; A D R Huitema; H Boot; A Cats; V D Doodeman; P H M Smits; L Vainchtein; H Rosing; I Meijerman; M Zueger; D Meulendijks; T D Cerny; J H Beijnen; J H M Schellens Journal: Cancer Chemother Pharmacol Date: 2015-02-13 Impact factor: 3.333
Authors: Matthias Schwab; Ulrich M Zanger; Claudia Marx; Elke Schaeffeler; Kathrin Klein; Jürgen Dippon; Reinhold Kerb; Julia Blievernicht; Joachim Fischer; Ute Hofmann; Carsten Bokemeyer; Michel Eichelbaum Journal: J Clin Oncol Date: 2008-02-25 Impact factor: 44.544
Authors: Thierry Lecomte; Jean-Marc Ferraz; Franck Zinzindohoué; Marie-Anne Loriot; David-Alexandre Tregouet; Bruno Landi; Anne Berger; Paul-Henri Cugnenc; Raymond Jian; Philippe Beaune; Pierre Laurent-Puig Journal: Clin Cancer Res Date: 2004-09-01 Impact factor: 12.531
Authors: Michael S Braun; Susan D Richman; Lindsay Thompson; Catherine L Daly; Angela M Meade; Julian W Adlard; James M Allan; Mahesh K B Parmar; Philip Quirke; Matthew T Seymour Journal: J Clin Oncol Date: 2009-10-26 Impact factor: 44.544
Authors: A Ruzzo; F Graziano; F Loupakis; D Santini; V Catalano; R Bisonni; R Ficarelli; A Fontana; F Andreoni; A Falcone; E Canestrari; G Tonini; D Mari; P Lippe; F Pizzagalli; G Schiavon; P Alessandroni; L Giustini; P Maltese; E Testa; E T Menichetti; M Magnani Journal: Pharmacogenomics J Date: 2007-06-05 Impact factor: 3.550
Authors: F Thomas; A A Motsinger-Reif; J M Hoskins; A Dvorak; S Roy; A Alyasiri; R J Myerson; J W Fleshman; B R Tan; H L McLeod Journal: Br J Cancer Date: 2011-11-01 Impact factor: 7.640
Authors: A Loganayagam; M Arenas Hernandez; A Corrigan; L Fairbanks; C M Lewis; P Harper; N Maisey; P Ross; J D Sanderson; A M Marinaki Journal: Br J Cancer Date: 2013-06-04 Impact factor: 7.640
Authors: Dan Rosmarin; Claire Palles; David Church; Enric Domingo; Angela Jones; Elaine Johnstone; Haitao Wang; Sharon Love; Patrick Julier; Claire Scudder; George Nicholson; Anna Gonzalez-Neira; Miguel Martin; Daniel Sargent; Erin Green; Howard McLeod; Ulrich M Zanger; Matthias Schwab; Michael Braun; Matthew Seymour; Lindsay Thompson; Benjamin Lacas; Valérie Boige; Nuria Ribelles; Shoaib Afzal; Henrik Enghusen; Søren Astrup Jensen; Marie-Christine Etienne-Grimaldi; Gérard Milano; Mia Wadelius; Bengt Glimelius; Hans Garmo; Milena Gusella; Thierry Lecomte; Pierre Laurent-Puig; Eva Martinez-Balibrea; Rohini Sharma; Jesus Garcia-Foncillas; Zdenek Kleibl; Alain Morel; Jean-Pierre Pignon; Rachel Midgley; David Kerr; Ian Tomlinson Journal: J Clin Oncol Date: 2014-03-03 Impact factor: 50.717
Authors: Jake M McDonnell; Brian Rigney; James Storme; Daniel P Ahern; Gráinne Cunniffe; Joseph S Butler Journal: Ir J Med Sci Date: 2022-08-13 Impact factor: 2.089
Authors: Jonathan E Knikman; Hans Gelderblom; Jos H Beijnen; Annemieke Cats; Henk-Jan Guchelaar; Linda M Henricks Journal: Clin Pharmacol Ther Date: 2020-11-12 Impact factor: 6.875